Provided by Tiger Trade Technology Pte. Ltd.

Insmed

145.30
-2.3000-1.56%
Pre-market: 151.005.70+3.92%07:11 EDT
Volume:3.40M
Turnover:493.50M
Market Cap:31.32B
PE:-22.63
High:149.20
Open:147.98
Low:142.59
Close:147.60
52wk High:212.75
52wk Low:60.40
Shares:215.55M
Float Shares:193.00M
Volume Ratio:1.06
T/O Rate:1.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4200
EPS(LYR):-6.4200
ROE:-249.28%
ROA:-28.99%
PB:42.38
PE(LYR):-22.63

Loading ...

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2026-03-23

Reuters
·
Mar 23

Insmed Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Mar 23

BUZZ-U.S. STOCKS ON THE MOVE-Energy firms, Cencora, Stryker

Reuters
·
Mar 23

Insmed up 10% at $150 after announcing results from Phase 3b ENCORE study

TIPRANKS
·
Mar 23

Insmed Shares Rise on Positive Results from Lung-Infection Drug Study

Dow Jones
·
Mar 23

BUZZ-U.S. STOCKS ON THE MOVE-United Airlines, Synopsys, PG&E

Reuters
·
Mar 23

Insmed Reports Positive Phase 3b ENCORE ARIKAYCE Results

TIPRANKS
·
Mar 23

S&P 500 Futures Rise In Premarket Trading; Insmed, Mobileye Global Lead

Dow Jones
·
Mar 23

Insmed (INSM) Receives a Buy from Wells Fargo

TIPRANKS
·
Mar 23

BUZZ- Insmed rises as late‑stage trial backs wider use of lung disease drug

Reuters
·
Mar 23

Insmed Shares up 8% Premarket on Positive Late‑Stage Trial Results for Lung Disease Drug

THOMSON REUTERS
·
Mar 23

Insmed reports Phase 3b ENCORE trial meets primary endpoint for ARIKAYCE in MAC lung disease

Reuters
·
Mar 23

Insmed Inc - Phase 3B Encore Study Met Primary and All Multiplicity-Controlled Secondary Endpoints

THOMSON REUTERS
·
Mar 23

Insmed Inc: Safety Profile Was Consistent With Known Safety Profile of Arikayce, and No New Safety Signals Were Observed

THOMSON REUTERS
·
Mar 23

Insmed Inc - to File Supplemental Nda for Arikayce With FDA and Submit Data to Pmda Japan in H2 2026

THOMSON REUTERS
·
Mar 23

Insmed Announces Positive Topline Results From Phase 3B Encore Study of Arikayce® (Amikacin Liposome Inhalation Suspension) in Patients With Mac Lung Disease

THOMSON REUTERS
·
Mar 23

U.S. RESEARCH ROUNDUP- ArriVent Biopharma, Aveanna Healthcare Holdings, EQT

Reuters
·
Mar 23

Brinsupri Launch Gives Insmed A New Respiratory Revenue Pillar

Simply Wall St.
·
Mar 19

Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Ansell (OtherANSLF)

TIPRANKS
·
Mar 19

Insmed Coverage Assumed by Jefferies at Buy

Dow Jones
·
Mar 17